Climb Bio Statistics
Total Valuation
Climb Bio has a market cap or net worth of $718.62 million. The enterprise value is $573.37 million.
| Market Cap | 718.62M |
| Enterprise Value | 573.37M |
Important Dates
The next estimated earnings date is Tuesday, August 11, 2026, before market open.
| Earnings Date | Aug 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Climb Bio has 57.26 million shares outstanding. The number of shares has increased by 15.07% in one year.
| Current Share Class | 57.26M |
| Shares Outstanding | 57.26M |
| Shares Change (YoY) | +15.07% |
| Shares Change (QoQ) | +1.24% |
| Owned by Insiders (%) | 0.92% |
| Owned by Institutions (%) | 36.82% |
| Float | 40.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.08 |
| P/TBV Ratio | 4.86 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 27.86, with a Debt / Equity ratio of 0.00.
| Current Ratio | 27.86 |
| Quick Ratio | 26.91 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -30.92% and return on invested capital (ROIC) is -21.93%.
| Return on Equity (ROE) | -30.92% |
| Return on Assets (ROA) | -21.27% |
| Return on Invested Capital (ROIC) | -21.93% |
| Return on Capital Employed (ROCE) | -40.51% |
| Weighted Average Cost of Capital (WACC) | 4.81% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.82M |
| Employee Count | 29 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +866.92% in the last 52 weeks. The beta is 0.10, so Climb Bio's price volatility has been lower than the market average.
| Beta (5Y) | 0.10 |
| 52-Week Price Change | +866.92% |
| 50-Day Moving Average | 10.73 |
| 200-Day Moving Average | 5.76 |
| Relative Strength Index (RSI) | 62.46 |
| Average Volume (20 Days) | 1,313,245 |
Short Selling Information
The latest short interest is 1.91 million, so 3.33% of the outstanding shares have been sold short.
| Short Interest | 1.91M |
| Short Previous Month | 2.09M |
| Short % of Shares Out | 3.33% |
| Short % of Float | 4.74% |
| Short Ratio (days to cover) | 2.19 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -60.08M |
| Pretax Income | -52.79M |
| Net Income | -52.79M |
| EBITDA | n/a |
| EBIT | -60.08M |
| Earnings Per Share (EPS) | -$0.79 |
Balance Sheet
The company has $109.56 million in cash and $479,000 in debt, with a net cash position of $145.83 million or $2.55 per share.
| Cash & Cash Equivalents | 109.56M |
| Total Debt | 479,000 |
| Net Cash | 145.83M |
| Net Cash Per Share | $2.55 |
| Equity (Book Value) | 148.09M |
| Book Value Per Share | 3.10 |
| Working Capital | 109.33M |
Cash Flow
In the last 12 months, operating cash flow was -$53.30 million and capital expenditures -$186,000, giving a free cash flow of -$53.49 million.
| Operating Cash Flow | -53.30M |
| Capital Expenditures | -186,000 |
| Depreciation & Amortization | 135,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -53.49M |
| FCF Per Share | -$0.93 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Climb Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15.07% |
| Shareholder Yield | -15.07% |
| Earnings Yield | -7.34% |
| FCF Yield | -7.44% |
Analyst Forecast
The average price target for Climb Bio is $20.93, which is 66.77% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $20.93 |
| Price Target Difference | 66.77% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |